Safety and Immunogenicity of CHIKV VLP Vaccine PXVX0317 in Adults ≥65 Years

NCT05349617 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

413

Enrollment

INDUSTRY

Sponsor class

Conditions

Chikungunya Virus

Interventions

BIOLOGICAL: CHIKV VLP/adjuvant
BIOLOGICAL: Placebo

Sponsor

Bavarian Nordic

Collaborators

[object Object]